Abstract:While chemotherapeutic agents were long solely associated with immunosuppression, clinical data demonstrate that the combination of some chemotherapies with immunomodulators can be beneficial against cancer. Defining combinations featuring optimal anticancer activity along with minimal toxicity remains however a major challenge. Clinical evidence suggests that immune responses in patients treated with combination therapies are associated with progression-free survival. Progress in understanding the mechanisms responsible for anticancer immune responses following chemotherapy administration facilitated the translation of relevant chemoimmunotherapy combinations in the clinic.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the potential and challenges of the combination of chemotherapy and immunotherapy (i.e., chemo - immunotherapy combination) in cancer treatment. Specifically, the paper emphasizes the following points: 1. **Historical Background**: The paper reviews the changes in the understanding of the relationship between chemotherapy and the immune system over the past few decades. Early studies believed that chemotherapy mainly functions by directly killing cancer cells, while ignoring the possible immune responses it may trigger. It was not until nearly 20 years ago that Richard Lake and Bruce Robinson proposed that the combination of chemotherapy and immunotherapy might produce a synergistic effect, and this hypothesis began to receive attention. 2. **Mechanism Exploration**: The paper discusses in detail how chemotherapy activates anti - tumor immune responses through methods such as inducing immunogenic cell death (ICD). For example, the combination of chemotherapy drugs such as Gemcitabine and anti - CD40 antibody has shown significant tumor regression effects in mouse experiments and can induce immune memory. 3. **Clinical Relevance**: The paper points out that although high - dose chemotherapy can lead to immunosuppression, an appropriate chemotherapy dose can trigger an immune response. For example, Adriamycin has better anti - leukemia activity in vivo than Daunorubicin, which may be related to its ability to activate the immune response. 4. **Clinical Application of Combination Therapy**: The paper introduces the progress of clinical attempts at chemo - immunotherapy combination in recent years. For example, in patients with microsatellite - stable (MSS) colorectal cancer, the combination of chemotherapy with anti - PD - L1 antibody (Durvalumab) and anti - CTLA - 4 antibody (Tremelimumab) has shown significant efficacy, prolonging the patients' progression - free survival (PFS) and inducing a stronger T - cell response. 5. **Future Directions**: The paper also proposes directions for further research, including exploring genetic and immune biomarkers related to the success of chemo - immunotherapy combination, in order to better guide clinical practice. In conclusion, this paper aims to promote the clinical application of chemo - immunotherapy combination in cancer treatment by reviewing and summarizing existing research, and to provide directions for future scientific research.

Chemoimmunotherapy combinations: translating basic knowledge into clinical successes

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment

Shining Light on Advanced NSCLC in 2017: Combining Immune Checkpoint Inhibitors.

Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors

Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice

Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review

The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review

Combination Strategies of Immunotherapy in Non-Small Cell Lung Cancer: Facts and Challenges

Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

Chemo-Immunotherapy: A New Trend in Cancer Treatment

Emerging strategies in cancer therapy combining chemotherapy with immunotherapy.

Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses

Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives

Prospects for combining targeted and conventional cancer therapy with immunotherapy

Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy

Clinically approved combination immunotherapy: Current status, limitations, and future perspective